Cancer Genetics, Inc. Will Showcase a Novel Diagnostic and Prognostic Test for Diffuse, Large B-Cell Lymphoma (DLBCL) at the American Society of Hematology Annual Meeting in New Orleans

RUTHERFORD, N.J., Nov. 25, 2013 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or the "Company"), an emerging leader in DNA-based diagnostics, is presenting data from its research collaboration with Memorial Sloan-Kettering Cancer Center ("MSKCC") at the American Society of Hematology ("ASH") 55th Annual Meeting and Exposition.

CGI's poster presents data using the Company's proprietary microarray for mature B-cell neoplasms ("MatBA®"). The poster (#4259), entitled "Cross-Platform Assessment of Genomic Imbalance In Diffuse Large B-Cell Lymphoma Identifies Novel Candidate Loci and Genes With Prognostic Value and Roles in Lymphomagenesis", will be presented on December 9, from 6:00 p.m. to 8:00 p.m. The goal of the study was to use a common genomic-based analytical approach across different clinical datasets, to identify genomic regions with robust prognostic value in DLBCL. Common and novel genomic imbalances in DLBCL were identified, of which some were found to have significance and could be included, with additional validation, in patient risk assessment.

"The MatBA®-DLBCL array is a valuable new tool for the prognostic evaluation of diffuse large B-cell lymphoma. The cross-platform evaluation of genomic gain and loss presented in this study is an important milestone not only in defining biomarkers but also in identifying novel candidate genes that are important in understanding lymphomagenesis as well as being potential therapeutic targets," says Dr. Chaganti, founder of CGI. "MatBA®-DLBCL is a member of CGI's MatBA series of mature B-cell lymphoma arrays and follows the highly successful MatBA®-CLL array currently in use for risk stratification of chronic lymphocytic leukemia" added Dr. Chaganti.

ASH is the world's largest professional society concerned with the cause and treatments of blood disorders. The ASH Annual Meeting is the premier hematology event of the year and is expected to attract more than 20,000 attendees from around the world. The 55th edition of ASH takes place December 7 to 10, 2013 in New Orleans, Louisiana. Cancer Genetics' team will be at booth 3025 during the event.

About Cancer Genetics:

Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Our state-of-the-art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. For further information, please see

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company's Form 10-Q for the quarter ended March 31, 2013 and other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.

CONTACT: Investor Relations RedChip Companies, Inc. Jon Cunningham, 800-733-2447, ext. 107 jon@redchip.comSource:Cancer Genetics